Valutazione prospettica della sola chirurgia conservativa del seno nel carcinoma duttale in situ a basso rischio (DCIS) (ELISA)
Valutazione prospettica della sola chirurgia conservativa del seno nel carcinoma duttale in situ a basso rischio definito da un test di espressione molecolare combinato con caratteristiche clinico-patologiche
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Descrizione dettagliata
A prospective cohort study, conducted in Canada, to prospectively evaluate whether the combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a group of women at very low risk of local recurrence following breast conserving surgery who do not require breast radiation therapy. We plan to screen 809 consenting women who will have their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate that 526 women will have an Oncotype DX DCIS score with a predicted 10-year risk of local recurrence ≤10%, these women will be enrolled and followed as part of the study.
At each centre, all patients with DCIS referred to radiation oncology will be documented. When a physician identifies an eligible patient, the patient will be approached by the referring physician or delegate to voluntarily provide informed consent to participate in this study. Consenting patients will be registered through the Ontario Clinical Oncology Group's (OCOG) web-based registration system. A two-step registration/enrollment process will be implemented.
Data related to the patient demographics, surgery details, tumour characteristics and ECOG performance will be collected. The patient's tumour specimen will be sent for analysis to Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will also receive the DCIS score results. Patients will be followed yearly up to 10 years. Bilateral mammograms and breast exams will be performed annually. The study data will be verified by source documentation.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Canada, V2S 0C2
- BC Cancer - Abbotsford Centre
-
Prince George, British Columbia, Canada, V2M 7E9
- BC Cancer - Centre for the North (Prince George)
-
Surrey, British Columbia, Canada, V3V 1Z2
- BC Cancer - Fraser Valley Centre
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer - Vancouver Centre
-
Victoria, British Columbia, Canada, V8R 6V5
- BC Cancer - Victoria
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- QE II HSC - Nova Scotia Cancer Centre
-
Sydney, Nova Scotia, Canada, B1P 1P3
- Cape Breton Cancer Centre
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Royal Victoria Regional Health Centre
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Thunder Bay, Ontario, Canada, P7B 6V4
- Regional Cancer Care, Thunder Bay Regional Health Sciences Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Science Centre -Odette Cancer Centre
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network - Princess Margaret Cancer Centre
-
Windsor, Ontario, Canada, N8W 2X3
- Windsor Regional Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Hôpital Charles Le Moyne (CISSS de la Montérégie-Centre)
-
Montreal, Quebec, Canada, H4A 3J1
- McGill University Health Centre
-
Montreal, Quebec, Canada, H2L 4M1
- CHUM - Centre Hospitalier de L'Université de Montréal
-
Québec, Quebec, Canada, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec - Université Laval
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie- Centre-du-Québec (CIUSSS MCQ) - Trois-Rivières
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N4H4
- Saskatoon Cancer Centre
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Prospective cohort study conducted in Canada in women with a low risk DCIS following breast conserving surgery who are candidates for radiation.
Eligibility status should be confirmed by the referring physician or delegate prior to enrollment. It is important that no exceptions are made to the eligibility criteria. Questions related to eligibility requirements and/or specific criteria should be addressed with OCOG prior to enrollment
Descrizione
Inclusion Criteria:
-
Female patient > 45 years of age with DCIS without microinvasion.
-
Tumour size ≤ 2.5cm.
-
Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on re-excision.*
* Patients with anterior margins and posterior margins ≥1 mm are eligible. Or if the dissection was confirmed to be taken to skin and down to fascia with no DCIS present at inked margins.
-
Oncotype DX DCIS score with a predicted 10-year risk of LR ≤10%.
Exclusion Criteria:
- Multifocal DCIS.
- History of any invasive breast cancer or non-invasive breast cancer in the ipsilateral breast.
- Synchronous or previous invasive or non-invasive breast cancer.
- Prior history of invasive cancer within the last 5 years, excluding non-melanoma skin cancers.
- ECOG performance status ≥3.
- Life expectancy <10 years.
- Geographic inaccessibility for follow-up.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
|---|
|
Single Arm Cohort
Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Ipsilateral local recurrence (LR)
Lasso di tempo: 5 Year
|
Defined as recurrent invasive or in situ cancer in the ipsilateral breast |
5 Year
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Ipsilateral invasive local recurrence
Lasso di tempo: 5 Year
|
defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast |
5 Year
|
|
Breast cancer recurrence-free interval (RFI)
Lasso di tempo: 5 Year
|
defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer |
5 Year
|
|
Distant disease-free survival (DDFS)
Lasso di tempo: 5 Year
|
defined as time from study registration to distant recurrence |
5 Year
|
|
Disease-free survival (DFS)
Lasso di tempo: 5 Year
|
defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause |
5 Year
|
|
Overall survival (OS)
Lasso di tempo: 5 Year
|
defined as time from registration to death of any cause |
5 Year
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Eileen Rakovitch, M.D., Sunnybrook Research Institute, Sunnybrook Health Science
- Investigatore principale: Tim Whelan, M.D, Juravinski Cancer Centre
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- OCOG-2021-ELISA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .